RecallRadar

FDA Drug recall D-0116-2025

Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, 4x1 mL Single Dose Vials, Rx only, Manufactured for and marketed by Halozy…

On 2024-12-18 the FDA classified a Class II recall of Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, 4x1 mL Single Dose Vials, Rx only, Manufactured for and marketed by Halozy… by Mckesson Medical Surgical Corporate Office, citing cGMP Deviations: Temperature excursion.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0116-2025
ClassificationClass II
Statusterminated
Initiated2024-09-11
Published2024-12-18
Last updated2026-09-13 11:52 UTC
CompanyMckesson Medical Surgical Corporate Office
Distributionn/a

Product

Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, 4x1 mL Single Dose Vials, Rx only, Manufactured for and marketed by Halozyme, Inc., 12390 El Camino Real San Diego California 92130, Distributed by Antares Pharma, Inc., Ewing, NJ NDC 18657-117-04

Reason

cGMP Deviations: Temperature excursion

Identifiers

ndc18657-117-01
ndc18657-117-02
ndc18657-117-04
ndc1000008319
ndc1000008206
ndc1000008205
code_infoSerial # 100000831961 100000820688 100000820689 100000820515

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0116-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.